DiaSorin Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance The quality controls are designed to verify the performance of the Luminex Verigene Blood Culture Gram-Positive and Gram-Negative tests. Decline in DiaSorin's Q2 MDx Revenues Offset by Strength in Immunodiagnostics Non-COVID-19 immunodiagnostics revenues drove an otherwise strong quarter for DiaSorin with continued growth in North America and Europe and slow improvement in China. In Brief This Week: HTG Molecular, Prenetics, DiaSorin, DermTech, NanoString Technologies, More News items for the week of June 5, 2023 DiaSorin Q1 Revenues Fall 19 Percent on COVID Sales Decline A 78 percent decline in COVID testing revenues was partially offset by revenue growth in its other diagnostics businesses. DiaSorin 2022 Revenues Grow 10 Percent For 2023, total revenues are expected to decline 14 percent year over year, and COVID-19 revenues are expected to be down 75 percent to €60 million. Mar 20, 2023 DiaSorin Gets FDA 510(k) for Molecular COVID-19/Flu Assay Mar 3, 2023 In Brief This Week: DermTech, Applied BioCode, Devyser, DiaSorin, Cytek, Bio-Techne, GenScript, More Feb 13, 2023 DiaSorin Selling Luminex Flow Cytometry Business to Cytek Biosciences for $46.5M Nov 9, 2022 DiaSorin Gets FDA 510(k) Clearance for Molecular CMV Test Oct 27, 2022 DiaSorin Q3 Revenues Dip 5 Percent as COVID-19 Test Sales Fall Oct 5, 2022 DiaSorin Gets $31M BARDA Funding for Point-of-Care Instrument Sep 14, 2022 DiaSorin Gains FDA 510(k) Clearance for COVID-19 PCR Test Aug 3, 2022 DiaSorin Posts 32 Percent Jump in Q2 Revenues May 20, 2022 Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19 May 6, 2022 DiaSorin Q1 Revenues Rise 34 Percent Despite Dip in COVID-19 Test Demand Mar 17, 2022 DiaSorin Expects 2022 Revenue Growth From Base Business, Luminex as COVID-19 Testing Declines Premium Mar 16, 2022 DiaSorin 2021 Revenues Rise 41 Percent on SARS-CoV-2, Luminex Sales Growth Feb 1, 2022 Genetic Analysis Receives CE Mark for Microbiome Test on Luminex Magpix Instrument Nov 11, 2021 DiaSorin Q3 Revenues Rise 51 Percent on Luminex Acquisition, Recovery of Non-COVID Test Sales Sep 20, 2021 DiaSorin Molecular Receives CE Mark for Multiplex COVID-19, Influenza Test Jul 30, 2021 DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand May 14, 2021 DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand Apr 13, 2021 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence Premium Apr 12, 2021 DiaSorin to Acquire Luminex for $1.8B Feb 25, 2021 Luminex Shares Surge on Rumor of Acquisition by DiaSorin Load More Breaking News SEC Concludes CareDx Investigation, Recommends No Enforcement Action Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance Adela Closes $48M Financing to Develop Cancer Monitoring, Early Detection Test 3EO Health At-Home Molecular COVID-19 Test Nabs FDA EUA Top Five Articles on GenomeWeb Last Week: IVDR Rollout, AI in Genomics, 10x vs. NanoString, More The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.